HTL Biotechnology has inaugurated its new production unit, HTL8, dedicated to the manufacture of pharmaceutical-grade polynucleotides, at its Javené site (Ille-et-Vilaine).
The €15m investment marks a structuring step in the group’s international development strategy and in the diversification of its biopolymer portfolio. It responds to the growing global demand for biopolymers intended for the most demanding therapeutic applications.
HTL8 is in line with HTL Biotechnology’s 2022-2026 €100m investment plan, which has contributed to its international development and the diversification of its portfolio in recent years. HTL Biotechnology is consolidating its positioning in the innovative segment of regenerative medicine and supporting the growth of global demand, particularly in Asian markets.
Polynucleotides are biopolymers made up of chains of nucleotides that are attracting increasing interest for their regenerative properties, including their ability to promote tissue repair, hydration and improved skin quality. HTL Biotechnology manufactures its polynucleotides from DNA extracted from wild Alaskan salmon milt, a co-product of the salmon industry recovered and used as a pharmaceutical raw material.
The new unit, dedicated to the purification of pharmaceutical-grade polynucleotides, strengthens HTL Biotechnology’s industrial capabilities and supports the development of new applications, particularly in regenerative medicine, ophthalmology, and dermatology.
HTL8 has been designed to meet industrial and pharmaceutical manufacturing standards. It combines equipment and automation with control of critical process parameters and quality and safety requirements.
“This new unit is fully in line with the €100 million investment plan launched in 2022. We are very committed to monitoring our markets and anticipating their developments by placing customer expectations at the heart of our strategy. Equipping ourselves with the most modern industrial capabilities to live up to our ambitions is key in this context. HTL8 is a perfect illustration of this: it anchors in France an industrial excellence capable of shining on a global scale, supporting our customers closely in their markets and contributing, through increasingly innovative pharmaceutical-grade biopolymers, to the healthcare solutions of tomorrow,” said François Fournier, CEO of HTL Biotechnology.


